CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, presented early-stage cost-effectiveness analysis of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results